THE COVID 19 SERVICES CATALYZE TRANSLATIONAL RESEARCH FINDINGS INTO PUBLIC HEALTH CHANGES TO ADDRESS THE NOVEL CORONAVIRUS PANDEMIC THROUGH IMPLEMENTATION OF STANDARDIZED SEROLOGY TESTING FOR ITS INTE

NIH RePORTER · NIH · N01 · $764,693 · view on reporter.nih.gov ↗

Abstract

The following support shall be provided for Therapeutic Development Branch: • Continuation of the "Integrated Data Resource for Rare Diseases" working with Advanced Biomedical Computational Science at Leidos Biomedical Research, Inc.; • Assay validation and non-GMP and GMP manufacturing of batches of drug substance and drug product; • Stability studies to support projects with GMP and / or non-GMP products; • Biodistribution / imaging and pharmacokinetic studies; • Consulting services for development of bioanalytical methods; • Regulatory services to support preclinical and / or clinical-stage projects; • Electron microscopy studies; • Gene expression and proteomic data analyses and cell-based screening studies; • Proteomic profiling, cell-based efficacy studies, and clinical trials for canine comparative oncology; • Laboratory animal support.

Key facts

NIH application ID
11053311
Project number
75N91019D00024-P00035-759102000003-60
Recipient
LEIDOS BIOMEDICAL RESEARCH, INC.
Principal Investigator
LEONARD FREEDMAN
Activity code
N01
Funding institute
NIH
Fiscal year
2024
Award amount
$764,693
Award type
Project period
2020-08-31 → 2024-08-30